Total Payments
$1,472
2024 Payments
$362.21
Companies
22
Transactions
60
Medicare Patients
8,890
Medicare Billing
$7.1M
Payment Breakdown by Category
Food & Beverage$1,382 (93.9%)
Education$89.86 (6.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,382 | 57 | 93.9% |
| Education | $89.86 | 3 | 6.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $464.85 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $137.44 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $115.15 | 4 | $0 (2024) |
| Merck Sharp & Dohme LLC | $107.44 | 5 | $0 (2024) |
| Daiichi Sankyo Inc. | $67.53 | 3 | $0 (2024) |
| Amgen Inc. | $62.49 | 3 | $0 (2022) |
| Genentech USA, Inc. | $61.52 | 3 | $0 (2023) |
| ABBVIE INC. | $61.47 | 2 | $0 (2024) |
| Incyte Corporation | $47.12 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $38.40 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $362.21 | 12 | Janssen Biotech, Inc. ($123.75) |
| 2023 | $255.26 | 9 | E.R. Squibb & Sons, L.L.C. ($40.91) |
| 2022 | $280.26 | 12 | Janssen Biotech, Inc. ($92.80) |
| 2021 | $159.50 | 7 | Janssen Biotech, Inc. ($81.04) |
| 2020 | $22.49 | 1 | E.R. Squibb & Sons, L.L.C. ($22.49) |
| 2019 | $217.04 | 12 | Janssen Biotech, Inc. ($57.19) |
| 2018 | $128.59 | 4 | Janssen Biotech, Inc. ($59.99) |
| 2017 | $46.75 | 3 | E.R. Squibb & Sons, L.L.C. ($22.08) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $32.31 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Oncology | ||||||
| 10/22/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $29.60 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.74 | General |
| Category: Hematology/Oncology | ||||||
| 09/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $30.42 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.38 | General |
| Category: Hematology/Oncology | ||||||
| 04/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.97 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $40.82 | General |
| Category: Oncology | ||||||
| 03/21/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $31.87 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: Oncology | ||||||
| 11/17/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.48 | General |
| 11/10/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: BioOncology | ||||||
| 10/09/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $37.86 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $33.18 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.41 | General |
| 08/17/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $36.00 | General |
| Category: Oncology | ||||||
| 03/16/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.50 | General |
| Category: Oncology | ||||||
| 02/15/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $36.24 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Oncology | ||||||
| 08/11/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, MEKINIST | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $39.75 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 2,174 | 146,042 | $5.1M | $1.1M |
| 2022 | 41 | 2,099 | 145,899 | $4.6M | $1.3M |
| 2021 | 43 | 2,239 | 178,126 | $7.9M | $2.3M |
| 2020 | 44 | 2,378 | 183,897 | $9.0M | $2.5M |
Total Patients
8,890
Total Services
653,964
Medicare Billing
$7.1M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 26 | 2,256 | $1.5M | $197,751 | 13.0% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 37 | 21,960 | $658,800 | $132,946 | 20.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 64 | 6,480 | $194,400 | $119,363 | 61.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 72 | 916 | $366,400 | $113,673 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 697 | $174,250 | $74,704 | 42.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 114 | 497 | $121,765 | $52,003 | 42.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 76 | 1,863 | $186,300 | $50,067 | 26.9% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 11 | 11,339 | $904,015 | $48,649 | 5.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 93 | 2,308 | $173,100 | $33,369 | 19.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 60 | 495 | $74,250 | $28,469 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 88 | 337 | $57,290 | $26,663 | 46.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 36 | 392 | $78,400 | $23,874 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 87 | 135 | $45,900 | $20,851 | 45.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 93 | 1,402 | $63,090 | $17,542 | 27.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 37 | 645 | $61,275 | $16,798 | 27.4% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 72 | 918 | $68,850 | $16,784 | 24.4% |
| 99491 | Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | Office | 2023 | 146 | 215 | $21,500 | $15,994 | 74.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 72 | $33,480 | $10,997 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $18,525 | $7,267 | 39.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 63 | 107 | $17,120 | $7,217 | 42.2% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 38 | 44,550 | $66,825 | $5,202 | 7.8% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 93 | $16,275 | $4,933 | 30.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 14 | 252 | $30,240 | $4,828 | 16.0% |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 2023 | 33 | 2,840 | $42,600 | $4,493 | 10.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 37 | 40 | $6,000 | $4,484 | 74.7% |
About Dr. Soren Caffey, MD
Dr. Soren Caffey, MD is a Hematology & Oncology healthcare provider based in Alexandria, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760415269.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Soren Caffey, MD has received a total of $1,472 in payments from pharmaceutical and medical device companies, with $362.21 received in 2024. These payments were reported across 60 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,382).
As a Medicare-enrolled provider, Caffey has provided services to 8,890 Medicare beneficiaries, totaling 653,964 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Alexandria, VA
- Active Since 07/08/2006
- Last Updated 08/06/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760415269
Products in Payments
- IMBRUVICA (Drug) $229.47
- DARZALEX (Biological) $157.26
- OPDIVO (Biological) $98.95
- KEYTRUDA (Biological) $84.86
- MEKINIST (Drug) $65.00
- RYBREVANT (Drug) $59.17
- Enhertu (Drug) $55.08
- KISQALI (Drug) $50.15
- JAKAFI (Drug) $47.12
- Revlimid (Drug) $36.52
- KRAZATI (Drug) $36.24
- CABOMETYX (Drug) $36.00
- Alecensa (Biological) $35.66
- ALUNBRIG (Drug) $33.18
- EPKINLY (Drug) $31.87
- ERLEADA (Drug) $28.35
- Kyprolis (Biological) $27.10
- Udenyca (Biological) $26.39
- Tecentriq (Biological) $25.86
- CINVANTI (Drug) $24.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Alexandria
Vinni Juneja, Md, MD
Hematology & Oncology — Payments: $35,341
Hematology & Oncology $35,341
Dr. Bassam Abi-Rached, M.d, M.D
Hematology & Oncology — Payments: $13,951
Hematology & Oncology $13,951
Dr. Howard Wold, M.d, M.D
Hematology & Oncology — Payments: $9,956
Hematology & Oncology $9,956
Dr. Hafez Halawani, Md, MD
Hematology & Oncology — Payments: $9,228
Hematology & Oncology $9,228
Dr. Anastas Provatas, Md, MD
Hematology & Oncology — Payments: $8,801
Hematology & Oncology $8,801
Dr. Christine Ince, M.d, M.D
Hematology & Oncology — Payments: $6,678
Hematology & Oncology $6,678